Skip to content
Mechanisms and Pharmaceutical RCTs episode artwork

Jan 17, 2025 16 min

Mechanisms and Pharmaceutical RCTs

from Emma•ism Hosted by Emma Søndergaard Jensen

In this episode, mechanisms and research are discussed. The question, ‘if we have a randomized control trial (RCT), can we do without knowledge of a mechanism?’ is answered. It is held that mechanisms do make a substantive difference to the optimization of a RCT. This is defended through two cases — the failed Duchenne Muscular Dystrophy Phase 3 trials in 2024 ran by Sarepta Therapeutics and Pfizer and the daptomycin 2005 trial to test its efficacy in patients Gram-positive community acquired pneumonia. Nancy Cartwright’s INUS contributors are put forth as a potential objection. However, an as-complete-as-possible concept of mechanistic understanding and reasoning is advocated for ultimately.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Mechanisms and Pharmaceutical RCTs

0:00 16:57

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Emma•ism?

This episode is 16 minutes long.

When was this Emma•ism episode published?

This episode was published on January 17, 2025.

Can I download this Emma•ism episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.